Tumour marker measurements in the diagnosis and monitoring of breast cancer

Cancer Treatment Reviews

Volumn 26, Issue 2, 2000, Pages 91-102

  Cheung, K L ^a   Graves, C R L ^a   Robertson, J F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Assays; Biochemical assessment; Blood tumour markers; Breast cancer; Diagnosis; Measurements; Monitoring; Therapeutic response

Indexed keywords

CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOTOXIC AGENT; MUCIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; BREAST CANCER; CANCER SCREENING; CANCER STAGING; CLINICAL PRACTICE; EARLY DIAGNOSIS; FOLLOW UP; HORMONAL THERAPY; HUMAN; LABORATORY TEST; METASTASIS; PATIENT MONITORING; REVIEW;

EID: 0034075529     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0151     Document Type: Review

References (97)

1. Statland B. E., Winkel P. Neoplasia. Kaplan L. A., Pesc A. J. Clinical chemistry: theory, analysis, and correlation: 2nd edition. 1989;734-735 CV Mosby, St Louis.
2. Sikorska H., Shuster J., Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detect Prevent. 12:1988;321-355.
3. Lahousen M., Stettner H., Pickel H., Urdl W., Purstner P. The predictive value of a combination of tumour markers in monitoring patients with ovarian cancer. Cancer. 60:1987;2228-2232.
4. Go V. L. W., Zamcheck N. The role of tumor markers in the management of colorectal cancer. Cancer. 50:1982;2618-2623.
5. McNeely M. D. D. Gastrointestinal function and digestive disease. Kaplan L. A., Pesc A. J. Clinical chemistry: theory, analysis, and correlation: 2nd edition. 1989;411-412 CV Mosby, St Louis.
6. Fletcher R. H. Carcinoembryonic antigen. Ann Int Med. 104:1986;66-73.
7. Mughal A. W., Hortogagyi G. N., Fritsche H. A., Buzdar A. U., Yap H. Y., Blumenschein G. R. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 249:1983;1881-1886.
8. Williams M. R., Turkes A., Pearson D., Twining P., Griffiths K., Blamey R. W. The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review. Eur J Surg Oncol. 14:1988;417-422.
9. Robertson J. F. R., Pearson D., Price M. R., Selby C., Pearson J., Blamey R. W., Howell A. Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother. 33:1991;403-410.
10. Lokich J. J., Zamcheck N., Lowenstein M. Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer. Ann Int Med. 89:1978;902-906.
11. Haagensen D. E., Kister S. J., Vandevoorde J. P., Gates J. B., Smart E. K., Hansen H. J., Wells S. A. Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer. 42:1978;1512-1519.
12. Doyle P. J., Nicholson R. I., Groome G. V., Blamey R. W. Carcinoembryonic antigen (CEA): its role as a tumour marker in breast cancer. Clin Oncol. 7:1981;53-58.
13. Lee Y. N. Serial tests of carcinoembryonic antigen in patients with breast cancer. Am J Clin Oncol. 6:1983;287-293.
14. Koldovsky U., Wargalla U., Hilkens J., Taylor-Papadimitrou J., Schnuerch H. G., Hilgers J. Reactions of monoclonal antibodies against membranes of human milk fat globules with uterine and cervical epithelia during proliferative and secretory stages. Prot Biol Fluids. 32:1984;239-242.
15. Hayes D., Sekine H., Ohao T., Abe M., Keefe K., Kufe D. W. Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest. 75:1985;1671-1678.
16. Hayes D. F., Zurawski V. R., Kufe D. W. Comparison of circulating CA15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 10:1986;1542-1550.
17. Pons-Anicet D. M. F., Krebs B. P., Namer M. Value of CA15.3 in the follow-up of breast cancer patients. Br J Surg. 55:1987;567-569.
18. Todini C., Hayes D. F., Gelman R., Henderson I. C., Kufe D. W. Comparison of CA15.3 and carcinoembryonic antigen in monitoring of the clinical course of patients with metastatic breast cancer. Cancer Res. 48:1988;4107-4112.
19. Robertson J. F. R., Pearson D., Price M. R., Selby C., Badley R. A., Pearson J., Blamey R. W., Howell A. Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer. 26:1990;1127-1132.
20. Colomer R., Ruibal A., Salvador L. Circulating tumour marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer. 64:1989;1674-1681.
21. Colomer R., Ruibal A., Genolla J., Rubio D., Del Campo J. M., Bodi R., Salvador L. Circulating CA15.3 levels in the post surgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat. 13:1989;123-133.
22. Molina R., Zanon G., Filella X., Moreno F., Jo J., Daniels M., Latre M. L., Gimenez N., Pahisa J., Velasco M., Ballesta A. M. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 36:1995;41-48.
23. Van Dalen A. New markers for breast carcinoma-associated antigen in comparison with CA15.3. Anticancer Res. 16:1996;2339-2343.
24. Reddish M. A., Helbrecht N., Almeida A. F., Madiyalakan R., Suresh M. R., Longenecker B. M. Epitope mapping of Mab B27.29 within the protein core of the malignant breast carcinoma-associated mucin antigen, MUC1. J Tumor Marker Oncol. 7:1992;19-27.
25. Graves R., Hilgers J., Fritsche H., Hayes D., Robertson J. F. R. MUC1 mucin assays for monitoring therapy in metastatic breast cancer. The Breast. 7:1998;181-186.
26. Hayes D. F., Kiang D. T., Korzun A., Tondini C., Wood W., Kufe D. CA15.3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol. 7:1988;38a.
27. Yasasever V., Camlica H., Karaloglu D., Dalay N. Utility of CA15.3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenonomen. Clin Biochem. 30:1997;53-56.
28. Martoni A., Zamagni C., Bellanova B., Zanichelli L., Vecchi F., Cacciari N., Strocchi E., Pannuti F. CEA, MCA, CA15.3 and CA549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur J Cancer. 31A:1995;1615-1621.
29. Garcia M. B., Blankenstein M. A., van der Wall E., Nortier J. W. R., Schornagel J. H., Thijssen J. H. H. Comparison of breast cancer mucin (BCM) and CA15.3 in human breast cancer. Breast Cancer Res Treat. 17:1990;69-76.
30. Deprés-Brummer P., Itzhaki M., Bakker P. J. M., Hoek F. J., Veenhof K. H. N., de Wit R. The usefulness of CA15.3, mucin-like carcinoma-associated antigen (MCA) and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. J Cancer Res Clin Oncol. 121:1995;419-422.
31. Price M. R. High molecular weight epithelial mucins as markers in breast cancer. Eur J Cancer Clin Oncol. 24:1988;1799-1804.
32. Robertson J. F. R. The role of serum tumour markers for monitoring therapy in metastatic breast cancer. Ligand Assay. 1:1996;257-262.
33. Robertson J. F. R., Jaeger W., Syzmendera J. J., Selby C., Coleman R., Howell A., Winstanley J., Jonssen P. E., Bombardieri E., Sainsbury J. R. C., Gronberg H., Kumpulainen E., Blamey R. W. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. Eur J Cancer. 35:1999;47-53.
34. Robertson J. F. R., Pearson D., Price M. R., Selby C., Blamey R. W., Howell A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer. 64:1991;757-763.
35. Dixon A. R. Tumour markers - a logical approach to the guidance of therapy in advanced breast cancer? Doctor of Medicine Thesis, University of Nottingham. 1991.
36. Dixon A. R., Jönrup I., Jackson L., Chan S. Y., Badley R. A., Blamey R. W. Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA15.3: fact or fiction? Disease Markers. 9:1991;167-174.
37. Dixon A. R., Jackson L., Chan S. Y., Badley R. A., Blamey R. W. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer. 68:1993;181-185.
38. Williams M. R., Turkes A., Pearson D., Griffiths K., Blamey R. W. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer. 61:1990;126-132.
39. Coombes R. C., Powles T. J., Gazet J. C., Ford H. T., McKinna A., Abbott Z., Gehrke C. W., Keyser J. W., Mitchell P. E. G., Patel S., Stimson W. H., Worwood M., Jones M., Neville A. M. Screening for metastases in breast cancer: an assessment of biochemical and physical methods. Cancer. 48:1981;310-315.
40. Lamoreux G., Mandeville R., Poisson R., Legault-Poisson S., Jolicoeur R. Biologic markers in breast cancer: a multiparametric study. 1. Increased serum protein levels. Cancer. 49:1982;502-512.
41. Gion M. Serum markers in breast cancer management. The Breast. 1:1992;173-178.
42. Cantwell B., Fennelly J. J., Jones M. Evaluation of follow-up methods to detect relapse mastectomy in breast cancer patients. Ir J Med Sc. 151:1982;1-5.
43. Safi F., Kohler I., Röttinger E., Beger H. G. The value of the tumour marker CA15.3 in diagnosing and monitoring breast cancer. Cancer. 68:1991;574-582.
44. Al-Jarallah M. A., Behbehani A. E., El-Nass S. A., Temim L., Ebraheem A. K., Ali M. A. A., Szymendera J. J. Serum CA-15.3 and CEA patters in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol. 19:1993;74-79.
45. Jäger W., Krämer S., Palapelas V., Norbert L. Breast cancer and clinical utility of CA15.3 and CEA. Scand J Clin Lab Invest. 55:1995;87-92.
46. Iwase H., Kobayashi S., Itoh Y., Fukuoka H., Kuzushima T., Iwata H., Yamashita T., Naitoh A., Itoh K., Masaoka A. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res Treat. 33:1994;83-88.
47. Kleist S. V., Bombardieri E., Buraggi G., Gion M., Hertel A., Hör G., Noujaim a, Schwartz M., Senekowitsch R., Wittekind C. Immunodiagnosis of tumours. Eur J Cancer. 29A:1993;1622-1630.
48. Gion M., Mione R., Nascimben O., Valsecchi M., Gatti C., Leon A., Bruscagnin G. The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer. 63:1991;809-813.
49. O'Hanlon D. M., Kerin M. J., Kent P. J., Skehill R., Maher D., Grimes H., Given H. F. A prospective evaluation of CA15.3 in stage I carcinoma of the breast. J Am Coll Surg. 180:1995;210-212.
50. Robertson J. F. R. Blood tumour markers in breast cancer. Tumour Marker Update. 10:1998;31-37.
51. Geraghty J. G., Coveney E. C., Sherry F., O'Higgins N. J., Duffy M. J. CA15.3 in patients with locoregional and metastatic breast carcinoma. Cancer. 70:1992;2831-2834.
52. Coveney E. C., Geraghty J. G., Sherry F., McDermott E. W., Fennelly J. J., O'Higgins N. J., Duffy M. J. The clinical value of CEA and CA15.3 in breast cancer management. Int J Biol Markers. 10:1995;35-41.
53. O'Hanlon D. M., Kerin M. J., Kent P., Maher D., Grimes H., Given H. F. An evaluation of preoperative CA15.3 measurement in primary breast carcinoma. Br J Cancer. 71:1995;1288-1291.
54. Tomlinson I. P. M., Whyman A., Barrett J. A., Kremer J. K. Tumour marker CA15-3: possible uses in the routine management of breast cancer. Eur J Cancer. 31A:1995;899-902.
55. O'Brien D. P., Skehill R., Horgan P. G., Grimes H., Gough D. B., Given H. F. CA15.3: a reliable indicator of metastatic bone disease in breast cancer patients. Ann R Coll Surg Engl. 74:1992;9-12.
56. Buffaz P. D., Gauchez A. S., Caravel J. P., Vuillez J. P., Cura C., Agnius-Delord C., Fagret D. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur J Nu Med. 26:1999;8-11.
57. Eur J Surg Oncol. 25:1999;3-23.
58. Krieger G., Kehl A., Wander H. E., Salo A. M., Rauschecker H. F., Nagel G. A. Clinical significance of circulating immune complexes (CIC) in patients with metastatic breast cancer. Int J Cancer. 31:1983;207-211.
59. Van Dalen A., Heering K. J., Barak V., Peretz T., Cremaschi A., Geroni P., Gion M., Saracchini S., Molina R., Namer M., Stieber P., Sturgeon C., Leonard R. C. F., Einarsson R. Treatment response in metastatic breast cancer: a multicentre study comparing UICC criteria and tumour marker changes. The Breast. 5:1996;82-88.
60. Robertson J. F. R. Prospective confirmation of a biochemical index for measuring therapeutic efficacy in metastatic breast cancer in a multicentre study. The Breast. 5:1996;372-373.
61. Wojtacki J., Dziewulska-Bokiniec A., Rolka-Stempniewicz G. Usefulness of CA15-3 antigen determination for evaluation of response to second-line chemotherapy in patients with breast cancer: preliminary study. Polskie Archiwum Medycyny Wewnetrznej. 97:1997;343-350.
62. Willsher P. C., Beaver J., Blamey R. W., Robertson J. F. R. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA15.3 and CEA. Anticancer Res. 15:1995;1609-1611.
63. Cheung, K. L. Sadozye, A. H. Chan, S. Y. Blamey, R. W. Evans, A. J. Robertson, J. F. R. The role of blood tumour markers in directing cytotoxic therapy in advanced breast cancer [In preparation].
64. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Cancer. 39:1977;1289-1293.
65. Brown A. L., Middleton G., MacVicar A. D., Husband J. E. S. T1 weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol. 53:1998;493-501.
66. J Clin Oncol. 14:1996;2843-2877.
67. Whitlock, J. P. L. Evans, A. J. Jackson, L. Chan, S. Y. Robertson, J. F. R. Imaging of metastatic breast cancer: distribution and radiological assessment of involved sites at presentation [In preparation].
68. Robertson J. F. R., Whynes D. K., Dixon A., Blamey R. W. Potential for cost economics in guiding therapy in patients with metastatic breast cancer. Br J Cancer. 72:1995;174-177.
69. Rosselli Del Turco M., Palli D., Cariddi A., Ciatto S., Pacini P., Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. JAMA. 271:1994;1593-1597.
70. JAMA. 271:1994;1587-1592.
71. Palli D., Russo A., Saieva C., Ciatto S., Rosselli Del Turco M., Distante V., Pacini P. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. JAMA. 281:1999;1586.
72. Lancet. 1:1992;1-15, 71-85.
73. Molina R., Zanón G., Filella X., Moreno F., Jo J., Daniels M., Latre M. L., Giménez N., Pahisa J., Velasco M., Ballesta A. M. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 36:1995;41-48.
74. Molina R., Jo J., Zanon G., Filella X., Farrus B., Muñoz M., Latre M. L., Pahisa J., Velasco M., Fernandez P., Estapé J., Ballesta A. M. Utility of c- erb B2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer. 74:1996;1126-1131.
75. Molina R., Gion M. Use of blood tumour markers in the detection of recurrent breast cancer. The Breast. 7:1998;187-109.
76. Jäger W., Merkle E., Lang N. Increasing serum tumour markers as decision criteria for hormone-therapy of metastatic breast cancer. Tumor Biol. 12:1994;60-66.
77. Nicolini A., Anselmi L., Michelassi C., Carpi A. Prolonged survival by "early" salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer. 76:1997;1106-1111.
78. Murray A., Willsher P., Price M. R., Dixon A. R., Robertson J. F. R. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15.3 and CEA in breast cancer. Anticancer Res. 17:1997;1945-1949.
79. Nicolini A., Colombini C., Luciani L., Carpi A., Giuliani L. Evaluation of serum CA15.3 determination with CEA and TPA in the postoperative follow-up of breast cancer patients. Br J Cancer. 64:1991;154-158.
80. Sonoo H., Kuerbayashi J. Serum tumour marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today. 26:1996;250-257.
81. Van Dalen A. TPS in breast cancer - a comparative study with carcinoembryonic antigen and CA15.3. Tumour Biol. 13:1992;10-17.
82. Einarsson R. TPS - a cytokeratin marker for therapy control in breast cancer. Scan J Clin Lab Invest. 55:1995;113-115.
83. Van Dalen A. Is TPS able to assist in decision making in breast cancer? In: Tumour associated antigens, oncogenes, receptors, cytokines in tumour diagnosis and therapy at the beginning of the nineties. 6th Symposium on Tumour Markers, Hamburg, 1991.
84. Harris L., Lüftner D., Jager W., Robertson J. F. R. C- erb B2 in serum of patients with breast cancer. Int J Biol Markers. 14:1999;8-15.
85. Tagliabue E., Ménard S., Robertson J. F. R., Harris L. C- erb B2 expression in primary breast cancer. Int J Biol Markers. 14:1999;16-26.
86. Lüftner D., Schinabel S., Possinger K. C- erb B2 in serum of patients receiving fractionated paclitaxel chemotherapy. Int J Biol Markers. 14:1999;55-59.
87. Weidner N., Semple J. P., Welch W. R., Folkman J. Tumour angiogenesis and metastases - correlation in invasive breast carcinoma. N Engl J Med. 324:1991;1-8.
88. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E. N., Moore D. H., Meli S., Gasparini G. Tumour angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 84:1992;1875-1887.
89. Magennis D. P. Angiogenesis: a new prognostic marker for breast cancer. Br J Biomed Sc. 55:1998;214-220.
90. Wu J. Apoptosis and angiogenesis: two promising tumor markers in breast cancer. Anticancer Res. 16:1996;2233-2239.
91. Blomqvist C., Elomaa I., Virkkunen P., Porkka L., Karonen S. L., Risteli J. The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy and biochemical markers of bone metabolism. Cancer. 60:1987;2907-2912.
92. Blomqvist C., Risteli L., Risteli J., Virkkunen P., Sarna S., Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer. 73:1996;1074-1079.
93. Plebani M., Bernardi D., Zaninotto M., De Paoli M., Secchiero S., Sciacovelli L. New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clin Biochem. 29:1996;67-72.
94. Tahtela R., Tholix E. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res. 16:1996;2289-2293.
95. Yamamoto I., Miura H., Kigami Y., Yamamura Y., Ohta T., Yuu I., Yamamoto Y., Morita R. Detection of bone metastases by serial measurement of C-terminal telopeptide of type I collagen in patients with malignancy. Kakuigaku. 33:1996;423-429.
96. Shimozuma K., Sonoo H., Fukunaga M., Ichihara K., Aoyama T., Tanaka K. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol. 29:1999;16-22.
97. Berruti A., Dogliotti L., Gorzegno G., Torta M., Tampellini M., Tucci M., Cerutti S., Frezet M. M., Stivanello M., Sacchetto G., Angeli A. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem. 45:1999;1240-1247.